Receptor Discordance of Metastatic Breast Cancer Depending on the Molecular Subtype.
Breast cancer
Metastases
Personalized medicine
Receptor status
Journal
Breast care (Basel, Switzerland)
ISSN: 1661-3791
Titre abrégé: Breast Care (Basel)
Pays: Switzerland
ID NLM: 101254060
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
08
10
2019
accepted:
12
02
2020
entrez:
15
1
2021
pubmed:
16
1
2021
medline:
16
1
2021
Statut:
ppublish
Résumé
Almost 30% of all women with early-stage breast cancer develop metastases. Treatment of metastatic disease is often based on the immunohistochemical information of the primary tumor, despite possible discordance of the hormone and Her2 receptor status. The aim of this study was to compare the receptor status of the primary tumor with the metastasis, and to evaluate for receptor discordance with regard to the molecular subtype, receptor status, and the localization of the metastases. We retrospectively analyzed the data of all consecutive women with metastatic breast cancer, who underwent treatment at the Medical University Vienna between 2009 and 2016. Associations were calculated using the χ We identified 213 metastatic breast cancer patients, of whom 67 (31.5%) showed a discordant receptor status. Out of 32 patients with luminal A subtype, 14 (43.8%) had a switch of at least one receptor; 27 of 53 patients (50.9%) with luminal B subtype and 21 of 32 patients (65.6%) with Her2+ subtype showed receptor discordance; for triple-negative disease, 5 of 19 patients (36.3%) had a switch of at least one receptor. In 63 samples of bone metastases, 13 (20.6%) had discordant estrogen receptor status ( Our data show high rates of receptor discordance in metastatic breast cancer. Apart from the primary tumor, the immunohistochemical receptor status of the metastasis needs to be verified. This can lead to a change in treatment and prognosis.
Identifiants
pubmed: 33447240
doi: 10.1159/000506464
pii: brc-0015-0648
pmc: PMC7768158
doi:
Types de publication
Journal Article
Langues
eng
Pagination
648-654Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Breast Cancer Res Treat. 2018 May;169(1):9-23
pubmed: 29353366
Oncologist. 2010;15(11):1164-8
pubmed: 21041379
Breast Cancer Res. 2008;10 Suppl 4:S4
pubmed: 19128442
Zhonghua Wai Ke Za Zhi. 2017 Feb 1;55(2):99-103
pubmed: 28162207
J Intern Med. 2013 Aug;274(2):113-26
pubmed: 23844915
Oncologist. 2005;10 Suppl 3:20-9
pubmed: 16368868
J Clin Oncol. 2012 Feb 20;30(6):587-92
pubmed: 22124102
Nature. 2011 Apr 7;472(7341):90-4
pubmed: 21399628
BMC Cancer. 2018 Feb 20;18(1):203
pubmed: 29463223
Acta Oncol. 2013 Nov;52(8):1649-56
pubmed: 23327413
Virchows Arch. 2017 Mar;470(3):275-283
pubmed: 28101678
Clin Cancer Res. 2008 Dec 15;14(24):7988-99
pubmed: 19088015
Oncologist. 2008 Nov;13(11):1134-6
pubmed: 18987048
PLoS One. 2019 May 22;14(5):e0217036
pubmed: 31116801
Med Hypotheses. 2005;64(6):1182-7
pubmed: 15823713
Ann Oncol. 2009 Sep;20(9):1499-1504
pubmed: 19299408
Breast Cancer Res Treat. 2014 Feb;143(3):507-15
pubmed: 24414130
Cancer Manag Res. 2018 Nov 05;10:5329-5338
pubmed: 30464629
Oncology. 2013;84(6):319-25
pubmed: 23615456
Int J Mol Sci. 2017 Nov 15;18(11):
pubmed: 29140300
Oncologist. 2006 Sep;11(8):868-77
pubmed: 16951390
Oncology. 2013;84(3):150-7
pubmed: 23257904
J Clin Pathol. 2009 Jun;62(6):542-6
pubmed: 19474354
Oncologist. 2013 Jun;18(6):667-74
pubmed: 23723333